Evommune, Inc.
EVMN
$18.41
-$1.82-9.00%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.00M | 3.00M | 7.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.00M | 3.00M | 7.00M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3.00M | 3.00M | 7.00M | -- | -- |
| SG&A Expenses | 13.88M | 13.63M | 12.77M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.00M | 84.29M | 77.01M | -- | -- |
| Operating Income | -76.00M | -81.29M | -70.01M | -- | -- |
| Income Before Tax | -64.76M | -78.58M | -66.81M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.76 | -78.58 | -66.81 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.76M | -78.58M | -66.81M | -- | -- |
| EBIT | -76.00M | -81.29M | -70.01M | -- | -- |
| EBITDA | -74.55M | -79.90M | -68.73M | -- | -- |
| EPS Basic | -5.07 | -22.40 | -21.51 | -- | -- |
| Normalized Basic EPS | -3.10 | -13.93 | -13.37 | -- | -- |
| EPS Diluted | -5.07 | -22.40 | -21.51 | -- | -- |
| Normalized Diluted EPS | -3.10 | -13.93 | -13.37 | -- | -- |
| Average Basic Shares Outstanding | 52.29M | 40.54M | 39.99M | -- | -- |
| Average Diluted Shares Outstanding | 52.29M | 40.54M | 39.99M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |